The newest pharmaceutical behemoths to reach MFN pricing agreements with the White House are Eli Lilly and Novo Nordisk, who have agreed to sell their weight-loss medications to Americans at reduced costs.

We've had Eyes on the MASH activities, and the latest M&A between Novo Nordisk and Akero Therapeutics caught our eye. In IPF, Boehringer's newly approved Jascayde...

We've been keeping Eyes On the updates coming out along with the 2Q25 Results. Lots of news on strategic Plans, M&A, Clinical Data, and more. 

We've highlighted a few firms: Lilly, AbbVie, Pfizer, Novo Nordisk, BMS, Roche, Novartis, Merck, AstraZeneca, GSK, Viatris, Teva, and Amgen.

This week, we had eyes on data readouts, launch metrics, M&A, and more. Catch up with the news from Roche, AstraZeneca, Lundbeck, and AbbVie

While we've been curating 3Q23 Results reports, we've had eyes on drug approvals, Business Development activities, & even some patent ...